Abstract: Among candidate NRTI-SDRMs, there were six tenofovir-associated mutations including three which increased in prevalence (K65N, T69deletion, K70G/N/Q/T).
Method: Tenofovir-associated mutations were defined as A62V, K65R/N/E, S68G/N/D, T69 deletions, and K70E/Q/N/T/S/G.
Res
Result: Figure 1 shows the locations of the NRTI-SDRMs and the six candidate mutations (K65N, T69deletion and K70G/N/Q/T) within the three-dimensional structure of the polymerase coding region of p66 HIV-1 RT.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Result: Other low-frequency NRTI-related mutations were K70QE, F77L, T215AI and K219QE.
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
PMID: 32843050
2020
Antimicrobial resistance and infection control
Conclusion: Detected RAMs were M41L, K70Q, V75I, Q151M, M184V and T215F for NRTI; K103N and V108I for NNRTI; and L10F, K20I, M36I, M46I, I47V, I54L, L63H, L76V, V82S and L89I for PI/r.
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Abstract: Common TAMs were K70RTQNE (32.8%), K219QE (22.4%), D67N (17.2%) and T215IT (15.5%).
Res
Result: Additionally, 13.3% (6 out of the 45) needing first line drug change had the type 2 TAMs combination of T215Y, D67N and K70RTQNE which in combination diminish the effectiveness of zidovudine.
Result: Among the NRTI mutations, the most common Thymidine Analogue Mutations (TAM's) were K70RTQNE (32.8%), K219QE (22.4%), D67N (17.2%), T215IT (15.5%) and M41L (5.2%).
The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
Abstract: 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and I84M), two PIs major DRMs (M46I, M46L), seven nucleoside RT inhibitors DRMs (D67N, K70Q, K219R and M184L), and 32 non-nucleoside RT inhibitors DRMs (K103N, V179E, K238N, V179D, PMID: 29846534
2019
Clinical infectious diseases
Abstract: The thymidine analogue mutations, M184V/I and the tenofovir-associated DRMs K65R and K70E/Q/G/N/T accounted for 82.9%, 7.3%, and 1.4% of NRTI-associated TDR, respectively.
Method: Several additional DRMs not on the SDRM list were analyzed including (1) the primarily tenofovir disoproxil fumarate (TDF)-selected DRMs A62V, K65N, and K70G/N/Q/S/T and (2) the primarily rilpivirine (RPV)-selected DRMs E138A/G/K/Q, of which E138A is polymorphic, occurring in 1%-4% of viruses from ART-naive individuals.
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
HIV mutation literature information.
PMID: 
2021
Infection and drug resistance
Browser Board
Co-occurred Entities
Filtrator
ViMRT